{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:51:16Z","timestamp":1792511476870,"version":"4.5.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.ad.2016.05.019","type":"journal-article","created":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T14:03:36Z","timestamp":1474034616000},"page":"6-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management"],"prefix":"10.1016","volume":"108","author":[{"given":"S.J.E.","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Anforth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Carlos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Fernandez-Pe\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2016.05.019_bib0500","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1365-2133.2012.11155.x","article-title":"Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma","volume":"167","author":"Anforth","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2016.05.019_bib0505","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","article-title":"Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort","volume":"74","author":"Hwang","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2016.05.019_bib0510","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1001\/jamadermatol.2015.1745","article-title":"Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma","volume":"151","author":"Carlos","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ad.2016.05.019_bib0515","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40257-014-0083-7","article-title":"A review of novel therapies for melanoma","volume":"15","author":"Karimkhani","year":"2014","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ad.2016.05.019_bib0520","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nrclinonc.2013.245","article-title":"Mitigating the toxic effects of anticancer immunotherapy","volume":"11","author":"Gangadhar","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ad.2016.05.019_bib0525","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11864-014-0284-6","article-title":"Managing the skin toxicities from new melanoma drugs","volume":"15","author":"Mavropoulos","year":"2014","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.ad.2016.05.019_bib0530","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/CJI.0000000000000112","article-title":"Toxic epidermal necrolysis-like reaction with severe satellite cell necrosis associated with nivolumab in a patient with ipilimumab refractory metastatic melanoma","volume":"39","author":"Nayar","year":"2016","journal-title":"J Immunother"},{"key":"10.1016\/j.ad.2016.05.019_bib0535","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2016.05.019_bib0540","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ad.2016.05.019_bib0545","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1477-3163-3-6","article-title":"Constitutive activation of the Ras\u2013Raf signaling pathway in metastatic melanoma is associated with poor prognosis","volume":"3","author":"Houben","year":"2004","journal-title":"J Carcinog"},{"key":"10.1016\/j.ad.2016.05.019_bib0550","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.hoc.2009.04.001","article-title":"BRAF signaling and targeted therapies in melanoma","volume":"23","author":"Dhomen","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.ad.2016.05.019_bib0555","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ad.2016.05.019_bib0560","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","article-title":"Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF","volume":"140","author":"Heidorn","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.ad.2016.05.019_bib0565","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"Hatzivassiliou","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ad.2016.05.019_bib0570","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ad.2016.05.019_bib0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2015.01.018","article-title":"Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy","volume":"72","author":"Anforth","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2016.05.019_bib0580","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/archdermatol.2011.3080","article-title":"Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma","volume":"148","author":"Alloo","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ad.2016.05.019_bib0585","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/dsu.12035","article-title":"A novel treatment approach for extensive, eruptive, cutaneous squamous cell carcinomas in a patient receiving BRAF inhibitor therapy for metastatic melanoma","volume":"39","author":"Fathi","year":"2013","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ad.2016.05.019_bib0590","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1200\/JCO.2011.39.8594","article-title":"Systemic retinoid therapy for chemoprevention of nonmelanoma skin cancer in a patient treated with vemurafenib","volume":"30","author":"Anforth","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ad.2016.05.019_bib0595","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1111\/bjd.12519","article-title":"Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors","volume":"169","author":"Anforth","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2016.05.019_bib0600","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bjd.13200","article-title":"Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks","volume":"172","author":"Anforth","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2016.05.019_bib0605","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S1470-2045(12)70413-8","article-title":"Cutaneous toxicities of RAF inhibitors","volume":"14","author":"Anforth","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ad.2016.05.019_bib0610","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1755-148X.2012.01031.x","article-title":"Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors","volume":"25","author":"Anforth","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.ad.2016.05.019_bib0615","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/exd.12975","article-title":"Mechanisms of BRAFi induced hyperproliferative cutaneous conditions","volume":"25","author":"Ali","year":"2016","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.ad.2016.05.019_bib0620","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1634\/theoncologist.2012-0333","article-title":"Analysis of dermatologic events in vemurafenib-treated patients with melanoma","volume":"18","author":"Lacouture","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.ad.2016.05.019_bib0625","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jaad.2012.04.008","article-title":"Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study","volume":"67","author":"Chu","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2016.05.019_bib0630","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/CMR.0000000000000127","article-title":"Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma","volume":"25","author":"Anforth","year":"2015","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ad.2016.05.019_bib0635","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1200\/JCO.2011.41.1660","article-title":"Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition","volume":"30","author":"Zimmer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ad.2016.05.019_bib0640","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMc1108651","article-title":"Vemurafenib in melanoma with BRAF V600E mutation","volume":"365","author":"Dalle","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2016.05.019_bib0645","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1038\/jid.2013.512","article-title":"Dormant melanomas or changing nevi?","volume":"134","author":"Argenziano","year":"2014","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.ad.2016.05.019_bib0650","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2340\/00015555-1813","article-title":"High incidence of naevi-associated BRAF wild-type melanoma and dysplastic naevi under treatment with the class I BRAF inhibitor vemurafenib","volume":"94","author":"Goppner","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2016.05.019_bib0655","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/jid.2013.462","article-title":"Melanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopy","volume":"134","author":"Perier-Muzet","year":"2014","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.ad.2016.05.019_bib0660","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2016.05.019_bib0665","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2016.05.019_bib0670","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1634\/theoncologist.2012-0483","article-title":"Ipilimumab and its toxicities: a multidisciplinary approach","volume":"18","author":"Fecher","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.ad.2016.05.019_bib0675","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ad.2016.05.019_bib0680","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/bjd.13300","article-title":"Vemurafenib skin phototoxicity is indirectly linked to ultraviolet A minimal erythema dose decrease","volume":"171","author":"Brugiere","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2016.05.019_bib0685","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1056\/NEJMc1113752","article-title":"Ultraviolet A and photosensitivity during vemurafenib therapy","volume":"366","author":"Dummer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2016.05.019_bib0690","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/exd.12119","article-title":"Vemurafenib: an unusual UVA-induced photosensitivity","volume":"22","author":"Gelot","year":"2013","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.ad.2016.05.019_bib0695","first-page":"391","article-title":"Dabrafenib and its potential for the treatment of metastatic melanoma","volume":"6","author":"Menzies","year":"2012","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.ad.2016.05.019_bib0700","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/1060028013513009","article-title":"Dabrafenib therapy for advanced melanoma","volume":"48","author":"Trinh","year":"2014","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ad.2016.05.019_bib0705","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1001\/jamadermatol.2013.5278","article-title":"Vemurafenib-induced DRESS","volume":"149","author":"Wenk","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ad.2016.05.019_bib0710","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000439272","article-title":"Early-onset vemurafenib-induced DRESS syndrome","volume":"232","author":"Munch","year":"2016","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2016.05.019_bib0715","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/cup.12273","article-title":"Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma","volume":"41","author":"Pattanaprichakul","year":"2014","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.ad.2016.05.019_bib0720","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/bjd.12796","article-title":"Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma","volume":"170","author":"Sinha","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2016.05.019_bib0725","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/bjd.14201","article-title":"Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulphonamide compounds","volume":"174","author":"Bellon","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2016.05.019_bib0730","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/bjd.13522","article-title":"Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis","volume":"172","author":"Jeudy","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2016.05.019_bib0735","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ad.2015.03.008","article-title":"Toxic epidermal necrolysis induced by vemurafenib","volume":"106","author":"Lapresta","year":"2015","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2016.05.019_bib0740","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2016.05.019_bib0745","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ad.2016.05.019_bib0750","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1517\/14712598.2015.1026323","article-title":"Trametinib in the treatment of melanoma","volume":"15","author":"Thota","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ad.2016.05.019_bib0755","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2147\/DHPS.S39568","article-title":"New developments in the treatment of metastatic melanoma \u2013 role of dabrafenib\u2013trametinib combination therapy","volume":"6","author":"Luke","year":"2014","journal-title":"Drug Healthc Patient Saf"},{"key":"10.1016\/j.ad.2016.05.019_bib0760","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1470-2045(12)70269-3","article-title":"Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial","volume":"13","author":"Falchook","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ad.2016.05.019_bib0765","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1200\/JCO.2012.43.5966","article-title":"Phase II study of the MEK1\/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor","volume":"31","author":"Kim","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ad.2016.05.019_bib0770","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2016.05.019_bib0775","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/ajd.12124","article-title":"Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib","volume":"55","author":"Anforth","year":"2014","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.ad.2016.05.019_bib0780","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/CMR.0000000000000096","article-title":"Acneiform eruption in a patient with metastatic melanoma after ceasing combination dabrafenib\/trametinib therapy","volume":"24","author":"Uribe","year":"2014","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ad.2016.05.019_bib0785","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/sj.jid.5701155","article-title":"IGF-1 induces SREBP-1 expression and lipogenesis in SEB-1 sebocytes via activation of the phosphoinositide 3-kinase\/Akt pathway","volume":"128","author":"Smith","year":"2008","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.ad.2016.05.019_bib0790","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1470-2045(12)70270-X","article-title":"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial","volume":"13","author":"Infante","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ad.2016.05.019_bib0795","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40257-014-0088-2","article-title":"Dermatological toxicity associated with targeted therapies in cancer: optimal management","volume":"15","author":"Peuvrel","year":"2014","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ad.2016.05.019_bib0800","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2016.05.019_bib0805","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S1470-2045(14)70301-8","article-title":"Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study","volume":"15","author":"Ribas","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ad.2016.05.019_bib0810","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1158\/1078-0432.CCR-13-2054","article-title":"Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma","volume":"20","author":"Menzies","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ad.2016.05.019_bib0815","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2016.05.019_bib0820","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1517\/14740338.2013.795944","article-title":"Cancer immunotherapies, their safety and toxicity","volume":"12","author":"Alatrash","year":"2013","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ad.2016.05.019_bib0825","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1158\/2326-6066.CIR-13-0092","article-title":"Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy","volume":"1","author":"Johnson","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ad.2016.05.019_bib0830","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.clindermatol.2012.08.006","article-title":"Immunomodulatory therapy for melanoma: ipilimumab and beyond","volume":"31","author":"Callahan","year":"2013","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.ad.2016.05.019_bib0835","first-page":"245","article-title":"Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma","volume":"6","author":"Tosti","year":"2013","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.ad.2016.05.019_bib0840","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2011-01-325266","article-title":"Autoimmunity associated with immunotherapy of cancer","volume":"118","author":"Amos","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ad.2016.05.019_bib0845","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jaad.2014.07.033","article-title":"Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways","volume":"72","author":"Macdonald","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2016.05.019_bib0850","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ad.2016.05.019_bib0855","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/annonc\/mdq013","article-title":"Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study","volume":"21","author":"O\u2019Day","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ad.2016.05.019_bib0860","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","article-title":"A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma","volume":"15","author":"Weber","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ad.2016.05.019_bib0865","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4137\/CMO.S5855","article-title":"Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities","volume":"6","author":"Lemech","year":"2012","journal-title":"Clin Med Insights Oncol"},{"key":"10.1016\/j.ad.2016.05.019_bib0870","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/CMR.0000000000000017","article-title":"Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy","volume":"23","author":"Pintova","year":"2013","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ad.2016.05.019_bib0875","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jaad.2013.06.038","article-title":"Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis","volume":"69","author":"Ensslin","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2016.05.019_bib0880","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.3747\/co.20.1265","article-title":"Immune toxicities and long remission duration after ipilimumab therapy for metastatic melanoma: two illustrative cases","volume":"20","author":"Assi","year":"2013","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ad.2016.05.019_bib0885","doi-asserted-by":"crossref","first-page":"e53745","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network","volume":"8","author":"Voskens","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1016\/j.ad.2016.05.019_bib0890","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of immunotherapy for the practitioner","volume":"33","author":"Weber","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ad.2016.05.019_bib0895","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.4161\/21645515.2014.983409","article-title":"PD-1 and PD-L1 antibodies for melanoma","volume":"10","author":"Tsai","year":"2014","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.ad.2016.05.019_bib0900","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ad.2016.05.019_bib0905","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ad.2016.05.019_bib0910","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11864-015-0368-y","article-title":"Management of dermatologic complications of lung cancer therapies","volume":"16","author":"Pugliese","year":"2015","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.ad.2016.05.019_bib0915","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1158\/1078-0432.CCR-14-3061","article-title":"Pembrolizumab for treatment of patients with advanced or unresectable melanoma","volume":"21","author":"Sullivan","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ad.2016.05.019_bib0920","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jamaoncol.2015.2274","article-title":"Prognostic significance of cutaneous adverse events associated with pembrolizumab therapy","volume":"1","author":"Lo","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ad.2016.05.019_bib0925","article-title":"Histologic assessment of lichenoid dermatitis observed in patients with advanced malignancies on anti-Programmed cell Death-1 (anti-PD-1) therapy with or without ipilimumab","author":"Chou","year":"2016","journal-title":"Am J Dermatopatholg"},{"key":"10.1016\/j.ad.2016.05.019_bib0930","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1001\/jamadermatol.2015.3579","article-title":"Time-dependent measurement of adverse events","volume":"151","author":"Hwang","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ad.2016.05.019_bib0935","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/CMR.0000000000000260","article-title":"Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies","volume":"26","author":"Hwang","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ad.2016.05.019_bib0940","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ad.2016.05.019_bib0945","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/CMR.0000000000000155","article-title":"A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab","volume":"25","author":"Carlos","year":"2015","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ad.2016.05.019_bib0950","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/CMR.0000000000000263","article-title":"PD-1 inhibitors induced bullous lichen planus-like reactions: a rare presentation and report of three cases","volume":"26","author":"Wakade","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ad.2016.05.019_bib0955","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-15-2872","article-title":"Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy","author":"Goldinger","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ad.2016.05.019_bib0960","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2340\/00015555-2212","article-title":"Exacerbation of psoriasis during nivolumab therapy for metastatic melanoma","volume":"96","author":"Matsumura","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2016.05.019_bib0965","article-title":"Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma","author":"Kato","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2016.05.019_bib0970","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ad.2015.07.012","article-title":"Pembrolizumab: a new drug that can induce exacerbations of psoriasis","volume":"107","author":"Sahuquillo-Torralba","year":"2016","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2016.05.019_bib0975","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/jamadermatol.2015.0249","article-title":"Occurrence of psoriasiform eruption during nivolumab therapy for primary oral mucosal melanoma","volume":"151","author":"Ohtsuka","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ad.2016.05.019_bib0980","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ad.2016.05.019_bib0985","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.coi.2012.07.010","article-title":"Drug Reaction with Eosinophilia and Systemic Symptoms: an update on pathogenesis","volume":"24","author":"Camous","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.ad.2016.05.019_bib0990","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/CMR.0b013e3283570792","article-title":"Vemurafenib-induced neutrophilic panniculitis","volume":"22","author":"Monfort","year":"2012","journal-title":"Melanoma Res"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731016302319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731016302319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:05:48Z","timestamp":1757552748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731016302319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0001731016302319"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2016.05.019","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2016.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 AEDV. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}